It is our great pleasure to announce that the 2nd International Symposium in Quantitative Pharmacology in Drug Development and Regulation will be held in Xiamen, China, 29-31 October, 2010. The symposium will discuss the latest methodologies in pharmacometrics areas focusing on pharmacokinetics and pharmacodynmics (PK/PD) modeling and simulation in drug development, regulation and clinical applications. The meeting will be hosted by Chinese Society of Quantitative Pharmacology, Institute of Molecular Medicine of Huaqiao University, and Chinese Journal of Clinical Pharmacology and Therapeutics etc.
In recent years, the integration of PK and PD modeling and simulation have played a vital role to guide the decision making process on lead generation, optimization and product realization, virtually, in every stage of drug development. These approaches lead to a shift in drug development paradigm from empirical to model based drug development with reducing time and cost needed for drug development.
With the recent trend toward global drug development and clinical trials, China has been regarded by many as the next frontier for the pharmaceutical industry. Pfizer, Roche, GSK, Novartis and many others have established development centers in China. Also, through the government support, the drug development industry and related infrastructure have been growing rapidly in China.
The success of 2007 Nanjing ISQP has created a big momentum in promoting the related research in the field in China. We believe that ISQP conference Xiamen 2010 will also lend a platform for the scientific leaders in academia, regulatory authority and the pharmaceutical industry to discuss the opportunities and challenges ahead in global drug development and approval. We hope this symposium will contribute to enhancing exchanging mutual interests between Western and China in this very challenging area.
Thank you in advance for your participation and general support!
Organizing Committee of ISQP, Xiamen, China
WEBSITE: http://isqp-meeting.org/
DATE & VENUE
October 29-31, 2010. Xiamen International Seaside Hotel
LIST OF SPONSORS
Sponsors
l Chinese Society of Quantitative Pharmacology
l Institute of Molecular Medicine of Huaqiao University,
l Chinese Journal of Clinical Pharmacology and Therapeutics
Co-sponsors
l Pfizer Inc
l Engineering Research Center of Molecular Medicine, Ministry of Education, China
l Anhui Provincial Center for Drug Clinical Evaluation
l Science and Technology Bureau of Xiamen
SYMPOSIUM TOPICS
l Model based drug development: Regulatory/Academic/Industrial Perspectives and Case Studies in Selected Classes
l Modernization of Traditional Chinese Medicine
l Biologic development
l Gene Therapy
ORGANIZING COMMITTEE
Advisor (Ordered by Family Name)
l Chang-xiao Liu (President of Chinese Society of Pharmacokinetics, Academician )
l Xin-heng Liu（Foreign academician of Ukraine Academy of Sciences; Academician of Third World Academy of Sciences; Academician）
l Guo-wei Sang（Vice Chairman of the Standing Committee of the National People's Congress; Academician）
l Jing Qiu（President of Huaqiao University）
l Hong-hao Zhou (President Emeritus of Chinese Society of Pharmacokinetics; Academician)
l Yu-feng Zhao（Director of Department of Pharmacy of Xiamen University; Academician）
Honorary Chairman
l SUN Rui-yuan (President Emeritus of Chinese Society of Quantitative Pharmacology; Editor-in-Chief of Chinese Journal of Clinical Pharmacology and Therapeutics)
Chairman (Local)
Rui-an Xu ( Institute of Molecular Medicine of Huaqiao University, HuaQiao University)
Chairman (International)
l Jun Shi (MD, MS, FCP, Allergan, Inc. USA)
l Jeffrey S. Barrett (PhD, FCP, Director of Applied Pharamacokinetics, University of Pennsylvania. USA)
Vice Chairman
l Peter Milligan (Pfizer Inc)
International Advisory Committee (Ordered by Family Name)
l Jeffrey S. Barrett, University of Pennsylvania, USA
l Rene Bruno, Pharsight Corporation , USA
l Vijay Bhargava (Novartis, USA)
l Mathew During (Yale University, USA)
l Don McGregor（Ministry of Sceicne & Technology, New Zealand）
l Peter Milligan (Pfizer Inc)
l Jun Shi (Allergan, Inc. USA)
l Bob Powell (Roche, Asian Pacific Center)
l Lorin Roskos (MedImmune, USA)
l Niranjan Rao (Kyowa Pharmaceuticals, Inc, USA)
l Shashank Rohatagi（Daiichi-Sankyo Indian Development, USA）
Chinese Academic Committee (Ordered by Family Name)
l Chong-hong Chen (Fujian Medical University)
l Chun-ling Chen (Shanghai Medicilon Inc)
l Fei-hu Chen (Anhui Medical University)
l Neng-neng Cheng (Fudan University)
l Yi-ming Cui (No1 Affiliated Hospital, Beijing University)
l Xiu-ling Cui (Huaqiao University)
l Ze-neng, Cheng (Central South University)
l Guan-hua Du (Chinese Pharmacological Society)
l Yong Diao(Huaqiao University)
l Feng Guo (Pfizer (China) Research &am, p; Development Center)
l Bei Hu (Peking Union Medical College Hospital)
l Xiao-hui Huang (Anhui Medical University)
l Yang-bin Huang (Shanghai Newsummit Biopharma Co.Ltd)
l Ji Jiang (Peking Union Medical College Hospital)
l Zheng Jiao (Affiliated Huashan Hospital, Fudan University)
l Jun Li (Anhui Medical University)
l Jin-heng Li (Nanjing General Hospital of Nanjing Military Command of Chinese PLA)
l Wei Lu (Pharmaceutical College, Peking University)
l Xiao-dong Liu (China Pharmaceutical University)
l Xin-yan Li (Shanghai Jiaotong University)
l Jian-zhong Rui (Nanjing General Hospital of Nanjing Military Command of Chinese PLA)
l He Sun (Tianjin Tasly Pharmaceutical Co.,Ltd.)
l Hong-tao Song (Fuzhou General Hospital of Nanjing Military Region)
l Jian-guo Song (Wannan Medical College )
l Rui-yuan Sun (Anhui Provincial Center for Drug Clinical Evaluation)
l Ping-jun Wang(The Affiliated Yijishan Hospital of Wannan Medical College)
l Guang-ji Wang, China Pharmaceutical University
l Hui Wang (Guangdong Pharmaceutical University)
l Pei Wu (The Affiliated Yijishan Hospital of Wannan Medical College)
l Qing-chuan Wang (Fujian Medical University)
l Wei Wei (Anhui Medical University)
l Hai-tang Xie (Anhui Provincial Center for Drug Clinical Evaluation)
l Jian-hua Xu (Fujian Medical University)
l Ning-ning Xiong (Affiliated Hospital of Nanjing University of Traditional Chinese Medicine)
l Rui-an Xu (HuaQiao University)
l Rui-zao Yi (Third Institute of Oceanography，State Oceanic Administration)
l Bing-xiang Yuan (Xian Jiaotong University)
l He-qun Yin (CNIBR)
l Shou-jun Yuan (Beijing Academy of Military Sciences)
l Xi-yong Yu (Guangdong Provincial People’s Hospital)
l Yun-qing Yang (Xiamen University)
l Zong-hui Yuan (Huazhong Agricultural University)
l Lu-yong Zhang (China Pharmaceutical University)
l Qing-shan Zheng (Shanghai University of Traditional Chinese Medicine)
l Su Zeng, Su Zeng (Zhejiang University)
l Yin-di Zhang (Nanjing Medical University)
Preparation Committee (Ordered by Family Name)
l Jeffrey S. Barrett, University of Pennsylvania, USA
l Yong Diao (Institute of Molecular Medicine of Huaqiao University)
l Feng Guo (Pfizer (China) Research & Development Center)
l Xiao-hui Huang (School of Pharmacy, Anhui Medical University)
l Hui-ying Lv (Institute of Molecular Medicine of Huaqiao University)
l Juan Li (Chinese Journal of Clinical Pharmacology and Therapeutics)
l Yuan-fu Li (Wannan Medical College)
l Jianguo Li（AstraZeneca, USA）
l Yong-yao Lin (Science and Technology Bureau of Xiamen)
l Jin-yun Wu (Chinese Journal of Clinical Pharmacology and Therapeutics)
l Shao-yun Wu (Wannan Medical College)
l Diane Wang (Pfizer Inc)
l Chang-shui Xu (Science and Technology Bureau of Xiamen)
l Hai-tang Xie (Anhui Provincal Centre for Drug Clinical Evaluation; Chinese Journal of Clinical Pharmacology and Therapeutics)
l Hui-yong Yang (Institute of Molecular Medicine of Huaqiao University)
l Yun-qing Yang (Xiamen Unisersity)
Secretary-General
l Hai-tang Xie (Anhui Provincal Centre for Drug Clinical Evaluation; Chinese Journal of Clinical Pharmacology and Therapeu, tics, China)
l Yong Diao (Institute of Molecular Medicine of Huaqiao University)
l Xiao-hui Huang (School of Pharmacy, Anhui Medical University)
Deputy Secretary-Generals
l Juan Li (Chinese Journal of Clinical Pharmacology and Therapeutics)
l Hui-ying Lv (Institute of Molecular Medicine of Huaqiao University)
l Hui-yong Yang (Institute of Molecular Medicine of Huaqiao University)<, /SPAN>
SCIENTIFIC PROGRAM ( PROVISIONAL )
For more details, Please wait for the 3rd announcement.
|
Yaning Wang (FDA, USA)
Role of Pharmacometrics at FDA
|
|
Bob Powell（Roche, Asian Pacific Center）
Ethnicity Considerations in Global Drug Development and Local Regulatory Approval: Contrasting Where We Are to Where We Need to Be
|
|
Peter Milligan (Pfizer Inc)
Concept & Applications of Model-Based Drug Development
|
|
Mathew During (Yale University, USA)
"Recent Developments in Gene Therapy of Metabolic and Neurological Disorders"
With an Emphasis on Obesity and Parkinson's Disease.
|
|
Farzin Farzaneh（King’s College London, UK）：
Quantitative Analysis of Response Indicators in Cancer Patients Receiving Novel Cell- and Gene-Therapy Investigational Medicinal Products
|
|
Rene Bruno（Pharsight EU）
Modeling and Simulation of Clinical Tumor Progression Dynamics: Predicting Phase 3 Survival Outcomes from Tumor Size Measurements in Phase 2
|
|
Jeffrey S. Barrett (University of Pennsylvania, USA)
Design and Analysis of Pediatric Clinical Pharmacology Trials to Support Dosing Guidance in Children
|
|
Jun Shi (Allergan, Inc. USA)
k-PD Application and Limitations or M&S in Pediatric Drug Development
|
|
Jian-guo Song (Wannan Medical College )
Chronergy: an Important Role in Drug Development
|
|
Wei Wei (Anhui Medical University)
Surrogate Endpoints - Wish or Reality
|
|
Earl Hulihan （Medidata Solution, USA）
A Review of the Current Global Concepts for Data Integrity and Data Quality in Computerized Systems
|
|
Di Wu (The Children's Hospital of Philadelphia)
Dynamic Biological Systems: Systems Biology Approach in Biomedical Research and Drug Discovery"
|
|
Feng Guo (Pfizer (China) Research & Development Center)
Application of Modeling & Simulations in Oncology Drug Development
|
|
Shou-jun Yuan (Beijing Academy of Military Sciences)
The Comprehensive Considerations of Preclinical Evaluation for Anticancer Drugs and The Strategy for Immune Anticancer Therapy.
|
|
Hequn Yin （Novartis）
Application of Pharmacometrics in First-In-Man trials of Anticancer Agents
|
|
Guangli Ma (Pfizer (China) Research & Development Center)
PK/PD Modeling of Sutent
|
|
Liping Zhang （BMS, ,USA）
Diabetes Modeling and Its Application in Drug Development
|
|
SaeHeum Song（Daiichi-Sankyo Pharma Development, USA）
Blood Pressure Lowering Effect Modeling for the Prediction of Clinical Outcome and Clinical Response Characterization of the Clinically Evaluated: TRiple Fixed dose combination dose strengths of OM, AML and HCTZ.
|
|
Michael Tanzil
Modeling and Simulation in Medical Device R&D
|
|
Phylinda Chan (Pfizer Inc)
Utility of PK-PD Modelling with Viral Dynamics Model in Drug Development for HIV
|
|
Qing-shan Zheng (Shanghai University of Traditional Chinese Medicine)
Approaches of Modeling and Simulation in Analysis of Drug Interactions
|
|
Jian-zhong Rui (Nanjing General Hospital of Nanjing Military Command of Chinese PLA)
Population Pharmacokinetics/Dynamics of Anesthetic Drug and its Utility
|
|
Zheng Jiao (Affiliated Huashan Hospital, Fudan University)
Population PK/PD Modeling of Sirolimus and its Impact on Lipids and Blood Pressures in Chinese Renal Transplant Patients
|
|
Baralee Punyawudho (Chulalongkorn University)
Population Pharmacokinetics of Mycophenolate Mofetil in Thai Lupus Nephritis Patients
|
|
Xiao-dong Liu (China Pharmaceutical University)
Mechanism-Based Inhibition of CYP1A2 Involved in Fluoroquinolone-Theophylline Interaction
|
|
Renli Teng（Astra-Zeneca）
Antiplatelet Therapy for Atherothrombotic Disease: Ethnicity Considerations and Dose Adjustments
|
|
Dr. Ken Kim （West Coast Clinical Trial Center）
Bridging Concept and Ethnic Effect
|
|
Liang Zhao（FDA, USA）
Development of Mathematical Models to Describe Antibody Absorption
|
|
James Li （USA）
Modeling Drug Absorption and Assessement of Drug Bioavailability and Bioequivalence
|
|
Jianguo Li（AstraZeneca, USA）
Stability of Deconvolution Method to Assess Drug Release and Absoprtion : Select Right Absoprtion Model
|
|
Chuanpu Hu（Centocor Research and Development, Inc. USA）
Using the Population Approach for BE Assessment
|
|
Susan Zhou (USA)
Characterization of Time and Concentration Dependent Binary Response Data by Time-To-Event Analysis
|
|
Lorin Roskos
Application of PK-PD Modeling to the Development of Protein Drugs
|
|
Diane Wang (Pfizer Inc)
Standardized Visual Predictive Check for Model Evaluation / or Fixed Dosing for Biologics in Adult Clinical Trials
|
|
Chee Ng
Mechanism-Based Model for Therapeutic Monoclonal Antibodies and Regulatable Gene Therapy Products
|
|
Kam Hui（National Cancer Research Center, Singapore）
The Molecular Biology of Human Hepatocellualr Carcinoma
|
|
Don McGregor（Ministry of Sceicne & Technology, New Zealand）
5-TH and Hypertension
|
|
Ling Chen（GlaxoSmithKline R&D China）
Revitalizing Old Medicines with New Concepts in Molecular Pharmacology
|
|
Pik-to CHEUNG（University of Hong Kong）
Basic Muscle AAV Expression Model for GDNF/pro-GDNF in Mice
|
|
Bing Wang
Antigen-Sink: Myth, Characterization, and Impact on mAb Development
|
|
Hui Shao (Japan)
|
|
Tingxia Dong (Hong Kong)
Traditional Medicine (TMC) in Hong Kong
|
|
Ziren Su
Approval and Research of TMC in China
|
|
Shashank Rohatagi（Daiichi-Sankyo Pharma Development）
|
|
Nagy Habib（Imperial College London, UK）
|
|
Chun-ling Chen (Shanghai Medicilon Inc)
|
|
Sarapee Hirankarn
|
CALL FOR PAPERS
Abstract and paper must be written in English consisting of Title, Author (s), Address and Email. Abstract and paper must be informative rather than indicative, including Aim, Methods, Main Results and Keywords, emphasizing the new and important aspects. Please submit abstract and paper to iqpxm2010b@yahoo.cn or iqpxm2010a@yahoo.com .
VENUE
Xiamen International Seaside Hotel : http://www.seaside.cn/english/index1.asp
Hotel Introduction http://www.seaside.cn/english/in1.htm
REGISTRATION
For early planning purposes, all attendees of the Workshop are requested to fill out the Registration Form and return it to the secretariat of symposium no later than October 1, 2010.
Registration Fees
|
|
If paid before October 1, 2010
|
If paid after October 1, 2010
|
|
Regular participants
|
US$ 400
|
US$ 450
|
|
Student participants
|
US$ 300
|
US$ 350
|
CONTACT INFORMATION
For more information and other questions, please email to : iqpxm2010a@yahoo.com; iqpxm2010b@yahoo.cn; 2010IQPXM1@hqu.edu.cn; 2010IQPXM2@hqu.edu.cn.
Or contact Dr. Huiyong Yang at 086-0595-22692300, Dr. Juan Li at 086-0553-5738350, or Dr. Yinhui Lv at 086-0595-22690838.
|
Registration Form
|
|
Please fill in the blanks and return this form to: Dr. Huiyong Yang ; E-mail: iqpxm2010a@yahoo.com; iqpxm2010b@yahoo.cn；
|
|
Title: Prof.__ Dr. __ Mr.__ Mrs.__ Ms. __
Name: __________________________ ______________________________ ________________________
(Family/Surname) (First Name) (Middle initials)
Company/Institution: _________________________________________________________________________________
Mailing Address: ____________________________________________________________________________________________________
City: ___________________State/Province:___________________Postal Code:_____________Country: _______________
Tel:_________________________Fax:________________________ E-mail:______________________________________
Accommodation: Arrival: _______________ Dept:______________ # Nights:___________________
I expect to be accompanied by ___________________________________; NO.OF GUESTS ______________
|
京公网安备 11010202007922号
打印